tertomotide
Term · Oncology and biomedicine · MLC-T-ONC-017073
A synthetic peptide vaccine containing a 16-amino-acid human telomerase reverse transcriptase peptide(hTERT: 611-626) with potential antineoplastic activity. Vaccination with telomerase peptide vaccine GV1001, which binds multiple HLA class II molecules and harbors putative HLA class I epitopes, may activate the immune system to mount a cytotoxic T-lymphocyte (CTL) response against telomerase-expressing tumor cells. Telomerase, a reverse transcriptase normally repressed in healthy cells, is overexpressed in most tumor cell types and plays a key role in cellular proliferation.
| Identifier | MLC-T-ONC-017073 |
|---|---|
| Field | Oncology and biomedicine |
| References | National Cancer Institute Thesaurus (CC BY 4.0) |
Record as JSON
{
"id": "MLC-T-ONC-017073",
"term": "tertomotide",
"field": "Oncology and biomedicine",
"definition": "A synthetic peptide vaccine containing a 16-amino-acid human telomerase reverse transcriptase peptide(hTERT: 611-626) with potential antineoplastic activity. Vaccination with telomerase peptide vaccine GV1001, which binds multiple HLA class II molecules and harbors putative HLA class I epitopes, may activate the immune system to mount a cytotoxic T-lymphocyte (CTL) response against telomerase-expressing tumor cells. Telomerase, a reverse transcriptase normally repressed in healthy cells, is overexpressed in most tumor cell types and plays a key role in cellular proliferation.",
"references": [
"National Cancer Institute Thesaurus"
],
"url": "https://mlchart.com/terminology/oncology/tertomotide/"
}
Record 16,163 of 17,721 in Oncology and biomedicine terminology (MLC-0111). Request the full dataset.